Why the study?
Does cardiac sympathetic nerve imaging with 123-I MIBG predict mortality, morbidity, and ventricular tachyarrhythmias in patients with chronic heart failure?
Does cardiac sympathetic nerve imaging with 123-I MIBG predict mortality, morbidity, and ventricular tachyarrhythmias in patients with chronic heart failure?
123-I MIBG imaging serves as a powerful prognostic marker for mortality, morbidity, and ventricular arrhythmias in chronic heart failure, highlighting the need for standardized imaging criteria.
Supports prognostic use of 123-I MIBG in chronic HF; leaves open standardization of criteria and prospective validation.
The autonomic nervous system interacts in the pathophysiology of heart failure. Dysfunction of the sympathetic nervous system has been identified as an important prognostic marker in patients with chronic heart failure. At present, cardiac sympathetic nerve imaging with 123-iodine metaiodobenzylguanidine [123-I MIBG] has been employed most frequently for the assessment of cardiac sympathetic innervation and activation pattern. The majority of studies have shown that cardiac sympathetic dysfunction as assessed with 123-I MIBG imaging is a powerful predictor for heart failure mortality and morbidity. Additionally, 123-I MIBG imaging can be used for prediction of potentially lethal ventricular tachyarrhythmias in heart failure patients. At present however, the lack of standardization of 123-I MIBG imaging procedures represents an evident issue. Standardized criteria on the use of 123-I MIBG imaging will further strengthen the clinical use of 123-I MIBG imaging in heart failure patients.
No takes yet. Share an insight, caveat, or question.
Boogers et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: